The cuts at two Massachusetts plants follow further site closures and layoffs across the company over the past few years.

Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

Learn more about whether Blueprint Medicines Corporation or Zai Lab Limited is a better investment based on AAII's A+ ...

A bill introduced this legislative session aims to prohibit the sale of certain marijuana products to customers aged 21 to 25 ...

AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030. Learn more on ABBV stock here.

Q4 2024 Management View CEO Kevin Hykes highlighted strong revenue growth of $15.3 million for Q4 2024, representing a 36% increase year-over-year. U.S. Heart Failure revenues grew by 41%, supported ...

Therapists who work in long-term care know a lot about time management and productivity. We know that our billable time must closely match our time on the ...

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...

Learn more about whether Enovis Corporation or ICU Medical, Inc. is a better investment based on AAII's A+ Investor grades, ...

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...

MaxCyte, Inc. (NASDAQ: MXCT), a leading cell-engineering focused company, recently announced the acquisition of SeQure DX Inc., a market leader in on-target and off-target editing assessment services ...